Table 2.
Overview of the characteristics of the participants included in the analyses, with patient-, HIV-, and ART-related factors
| Items | n | % | Median (IQR) |
|---|---|---|---|
| Patient-related factors | |||
| Male sex | 172 | 80 | |
| Age (years) | 47 (37–54) | ||
| HIV transmission route | |||
| MSM | 108 | 50 | |
| Origin of HPC | 29 | 14 | |
| IVDU | 15 | 7.0 | |
| Other | 27 | 13 | |
| Unknown | 39 | 18 | |
| Comorbidities | 161 | 75 | |
| Psychiatric disorder | 63 | 29 | |
| Depression | 40 | 19 | |
| HBV | 10 | 4.7 | |
| HCV | 13 | 6.0 | |
| Cardiovascular risk factors | 51 | 24 | |
| Major vascular event | 11 | 5.1 | |
| Other | 108 | 50 | |
| Co-medication | 93 | 43 | |
| Psychiatric co-medication | 24 | 11 | |
| Cardiovascular co-medication | 50 | 23 | |
| Antiinfectives | 16 | 7.4 | |
| Other | 48 | 22 | |
| HIV-related factors | |||
| Time since HIV diagnosis (years) | 9 (4–18) | ||
| History of AIDS | 24 | 11 | |
| HIV-1 RNA VL (cp/mL) | 19 (19–49) | ||
| CD4 cells (n/μL) | 607 (410–850) | ||
| ART-related factors | |||
| ART duration (years) | 6 (3–14) | ||
| ART dosing and pill burden | |||
| STR | 65 | 30 | |
| MTR once daily | 103 | 48 | |
| MTR twice daily | 47 | 22 | |
| Current ART regimen | |||
| NRTI containing | 192 | 89 | |
| NNRTI containing | 90 | 42 | |
| PI containing | 75 | 35 | |
| CCR5 containing | 2 | 0.9 | |
| INI containing | 69 | 32 | |
Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; CCR5, C-C chemokine receptor 5 inhibitor; cp, copies; HBV, chronic hepatitis B infection; HCV, chronic hepatitis C infection; HIV, human immunodeficiency virus; HPC, high prevalence country; IQR, interquartile range; INI, integrase inhibitor; IVDU, intravenous drug use; MSM, men having sex with men; MTR, multi-tablet regimen; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STR, single-tablet regimen; VL, viral load.